Tranquilizer/Anxiolytics: Tandospirone

Li, Jie

doi:10.1007/978-3-319-56015-1_167-1

Jie Li⁶

44 Accesses

Abstract

Tandospirone, a selective 5-HT_1A receptor partial agonist, was developed and firstly marketed in Japan. It was designed for anxiety disorders at first. Yet with the emergence of new techniques, more details of its mechanism have been discovered and collected through increasingly more precise and sophisticated methods, along with a broader range of clinical indications being explored, found, and finally set on the basis of various experiments and trials. Regardless of increasing knowledge of its mechanism and the diversity of indications, to date, tandospirone remains an anxiolytic with its main indication for anxiety disorder and corresponding precautions, which makes it require a more thorough assessment than as any other medications before application.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

Albert PR, François BL. Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci. 2010;4:35. https://doi.org/10.3389/fnins.2010.00035.
Article CAS PubMed PubMed Central Google Scholar
Barbee JG. Memory, benzodiazepines, and anxiety: integration of theoretical and clinical perspectives. J Clin Psychiatry. 1993;54(Suppl):86–97; discussion 98–101
PubMed Google Scholar
Barbee JG, Black FW, Kehoe CE, Todorov AA. A comparison of the single-dose effects of alprazolam, buspirone, and placebo upon memory function. J Clin Psychopharmacol. 1991;11(6):351–6.
Article CAS PubMed Google Scholar
Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, MacDonald TM. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352(9137):1331–6. https://doi.org/10.1016/s0140-6736(98)04087-2.
Article CAS PubMed Google Scholar
Bolton JM, Cox BJ, Afifi TO, Enns MW, Bienvenu OJ, Sareen J. Anxiety disorders and risk for suicide attempts: findings from the Baltimore Epidemiologic Catchment area follow-up study. Depress Anxiety. 2008;25(6):477–81. https://doi.org/10.1002/da.20314.
Article PubMed Google Scholar
Bonanno G, Maura G, Raiteri M. Pharmacological characterization of release-regulating serotonin autoreceptors in rat cerebellum. Eur J Pharmacol. 1986;126(3):317–21. https://doi.org/10.1016/0014-2999(86)90065-8.
Article CAS PubMed Google Scholar
Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol. 1994;17(1):73–82. https://doi.org/10.1097/00002826-199402000-00008.
Article CAS PubMed Google Scholar
Boulenger JP, Squillace K, Simon P, Herrou M, Leymarie P, Zarifian E. Buspirone and diazepam: comparison of subjective, psychomotor and biological effects. Neuropsychobiology. 1989;22(2):83–9. https://doi.org/10.1159/000118597.
Article CAS PubMed Google Scholar
Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keller MB. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162(6):1179–87. https://doi.org/10.1176/appi.ajp.162.6.1179.
Article PubMed PubMed Central Google Scholar
Bruins Slot LA, Kleven MS, Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology. 2005;49(7):996–1006. https://doi.org/10.1016/j.neuropharm.2005.05.013. Epub 2005 Jul 11
Article CAS PubMed Google Scholar
Cadieux RJ. Azapirones: an alternative to benzodiazepines for anxiety. Am Fam Physician. 1996;53(7):2349–53.
CAS PubMed Google Scholar
Chamberlain SR, Müller U, Deakin JB, Corlett PR, Dowson J, Cardinal RN, Aitken MR, Robbins TW, Sahakian BJ. Lack of deleterious effects of buspirone on cognition in healthy male volunteers. J Psychopharmacol. 2007;21(2):210–5. https://doi.org/10.1177/0269881107068066. Erratum in: J Psychopharmacol. 2008 Aug;22(6):699
Article CAS PubMed Google Scholar
Chang CM, Wu EC, Chang IS, Lin KM. Benzodiazepine and risk of hip fractures in older people: a nested case-control study in Taiwan. Am J Geriatr Psychiatry. 2008;16(8):686–92. https://doi.org/10.1097/JGP.0b013e31817c6a99.
Article PubMed Google Scholar
Chaput Y, de Montigny C. Effects of the 5-hydroxytryptamine receptor antagonist, BMY 7378, on 5-hydroxytryptamine neurotransmission: electrophysiological studies in the rat central nervous system. J Pharmacol Exp Ther. 1988;246(1):359–70.
CAS PubMed Google Scholar
Chaput Y, Blier P, de Montigny C. In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci. 1986;6(10):2796–801. https://doi.org/10.1523/JNEUROSCI.06-10-02796.1986.
Article CAS PubMed PubMed Central Google Scholar
Claustre Y, Bénavidès J, Scatton B. 5-HT1A receptor agonists inhibit carbachol-induced stimulation of phosphoinositide turnover in the rat hippocampus. Eur J Pharmacol. 1988;149(1–2):149–53. https://doi.org/10.1016/0014-2999(88)90054-4.
Article CAS PubMed Google Scholar
Claustre Y, Benavides J, Scatton B. Potential mechanisms involved in the negative coupling between serotonin 5-HT1A receptors and carbachol-stimulated phosphoinositide turnover in the rat hippocampus. J Neurochem. 1991;56(4):1276–85. https://doi.org/10.1111/j.1471-4159.1991.tb11422.x.
Article CAS PubMed Google Scholar
Csanalosi I, Schweizer E, Case WG, Rickels K. Gepirone in anxiety: a pilot study. J Clin Psychopharmacol. 1987;7(1):31–3.
Article CAS PubMed Google Scholar
Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand. 2005;111(6):429–35. https://doi.org/10.1111/j.1600-0447.2005.00529.x.
Article CAS PubMed Google Scholar
Darrow EJ, Strahlendorf HK, Strahlendorf JC. Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapirone in vitro. Eur J Pharmacol. 1990;175(2):145–53. https://doi.org/10.1016/0014-2999(90)90225-u.
Article CAS PubMed Google Scholar
Den Boer JA, Westenberg HG, Klompmakers AA, van Lint LE. Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety. Biol Psychiatry. 1989;26(6):612–22. https://doi.org/10.1016/0006-3223(89)90086-3.
Article Google Scholar
Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci. 2005;25(47):10831–43. https://doi.org/10.1523/JNEUROSCI.2999-05.2005.
Article CAS PubMed PubMed Central Google Scholar
Done CJ, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology. 1994;33(3–4):411–21. https://doi.org/10.1016/0028-3908(94)90071-x.
Article CAS PubMed Google Scholar
Drebing CJ, Freedman R, Waldo M, Gerhardt GA. Unconjugated methoxylated catecholamine metabolites in human saliva. Quantitation methodology and comparison with plasma levels. Biomed Chromatogr. 1989;3(5):217–20. https://doi.org/10.1002/bmc.1130030509.
Article CAS PubMed Google Scholar
Eison AS. Azapirones: history of development. J Clin Psychopharmacol. 1990;10(3 Suppl):2S–5S.
Article CAS PubMed Google Scholar
Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K. Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT1B binding sites. Naunyn Schmiedeberg’s Arch Pharmacol. 1986;332(1):1–7. https://doi.org/10.1007/BF00633189.
Article CAS Google Scholar
Ennaceur A. One-trial object recognition in rats and mice: methodological and theoretical issues. Behav Brain Res. 2010;215(2):244–54. https://doi.org/10.1016/j.bbr.2009.12.036. Epub 2010 Jan 7
Article CAS PubMed Google Scholar
Evans SM, Troisi JR 2nd, Griffiths RR. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther. 1994;271(2):683–94.
CAS PubMed Google Scholar
Faludi G, Mirnics K. Synaptic changes in the brain of subjects with schizophrenia. Int J Dev Neurosci. 2011;29(3):305–9. https://doi.org/10.1016/j.ijdevneu.2011.02.013. Epub 2011 Mar 5
Article PubMed PubMed Central Google Scholar
Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry. 1997;42(7):568–76. https://doi.org/10.1016/S0006-3223(96)00440-4.
Article CAS PubMed Google Scholar
Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342–51. https://doi.org/10.1176/appi.ajp.2007.06111868. Epub 2008 Jan 2
Article PubMed Google Scholar
Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1982;43(12 Pt 2):103–8.
CAS PubMed Google Scholar
Fischette CT, Nock B, Renner K. Effects of 5,7-dihydroxytryptamine on serotonin1 and serotonin2 receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res. 1987;421(1–2):263–79. https://doi.org/10.1016/0006-8993(87)91296-0.
Article CAS PubMed Google Scholar
Fuchs E, Flügge G. Stress, glucocorticoids and structural plasticity of the hippocampus. Neurosci Biobehav Rev. 1998;23(2):295–300. https://doi.org/10.1016/s0149-7634(98)00031-1.
Article CAS PubMed Google Scholar
Gaynes BN, Magruder KM, Burns BJ, Wagner HR, Yarnall KS, Broadhead WE. Does a coexisting anxiety disorder predict persistence of depressive illness in primary care patients with major depression? Gen Hosp Psychiatry. 1999;21(3):158–67. https://doi.org/10.1016/s0163-8343(99)00005-5.
Article CAS PubMed Google Scholar
Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132(1):397–414. https://doi.org/10.1053/j.gastro.2006.11.002.
Article CAS PubMed Google Scholar
Godbout R, Chaput Y, Blier P, de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine – I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology. 1991;30(7):679–90. https://doi.org/10.1016/0028-3908(91)90175-b.
Article CAS PubMed Google Scholar
Goenjian AK, Yehuda R, Pynoos RS, Steinberg AM, Tashjian M, Yang RK, Najarian LM, Fairbanks LA. Basal cortisol, dexamethasone suppression of cortisol, and MHPG in adolescents after the 1988 earthquake in Armenia. Am J Psychiatry. 1996;153(7):929–34. https://doi.org/10.1176/ajp.153.7.929.
Article CAS PubMed Google Scholar
Gould E, Gross CG. Neurogenesis in adult mammals: some progress and problems. J Neurosci. 2002;22(3):619–23. https://doi.org/10.1523/JNEUROSCI.22-03-00619.2002.
Article CAS PubMed PubMed Central Google Scholar
Gould E, Tanapat P, McEwen BS, Flügge G, Fuchs E. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci USA. 1998;95(6):3168–71. https://doi.org/10.1073/pnas.95.6.3168.
Article CAS PubMed PubMed Central Google Scholar
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41–51. https://doi.org/10.1016/j.schres.2004.09.009.
Article PubMed Google Scholar
Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 1993;34(10):702–12. https://doi.org/10.1016/0006-3223(93)90043-d.
Article CAS PubMed Google Scholar
Hamik A, Oksenberg D, Fischette C, Peroutka SJ. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry. 1990;28(2):99–109. https://doi.org/10.1016/0006-3223(90)90627-e.
Article CAS PubMed Google Scholar
Hammerstad JP, Carter J, Nutt JG, Casten GC, Shrotriya RC, Alms DR, Temple D. Buspirone in Parkinson’s disease. Clin Neuropharmacol. 1986;9(6):556–60. https://doi.org/10.1097/00002826-198612000-00007.
Article CAS PubMed Google Scholar
Hart RP, Colenda CC, Hamer RM. Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects. Am J Psychiatry. 1991;148(1):73–7. https://doi.org/10.1176/ajp.148.1.73.
Article CAS PubMed Google Scholar
Hashizume H, Takigawa M. Anxiety in allergy and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2006;6(5):335–9. https://doi.org/10.1097/01.all.0000244793.03239.40.
Article CAS PubMed Google Scholar
Hawton K, Casañas I, Comabella C, Haw C, Saunders K. Risk factors for suicide in individuals with depression: a systematic review. J Affect Disord. 2013;147(1–3):17–28. https://doi.org/10.1016/j.jad.2013.01.004. Epub 2013 Feb 12
Article PubMed Google Scholar
Hinton DE, Park L, Hsia C, Hofmann S, Pollack MH. Anxiety disorder presentations in Asian populations: a review. CNS Neurosci Ther. 2009;15(3):295–303. https://doi.org/10.1111/j.1755-5949.2009.00095.x.
Article PubMed PubMed Central Google Scholar
Hirose A, Sasa M, Akaike A, Takaori S. Inhibition of hippocampal CA1 neurons by 5-hydroxytryptamine, derived from the dorsal raphe nucleus and the 5-hydroxytryptamine1A agonist SM-3997. Neuropharmacology. 1990;29(2):93–101. https://doi.org/10.1016/0028-3908(90)90048-v.
Article CAS PubMed Google Scholar
Hirschfeld RM. The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. Prim Care Companion. J Clin Psychiatry. 2001;3(6):244–54. https://doi.org/10.4088/pcc.v03n0609.
Article Google Scholar
Horiguchi M, Meltzer HY. The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology. 2012;221(2):205–15. https://doi.org/10.1007/s00213-011-2561-4. Epub 2012 Jan 7
Article CAS PubMed Google Scholar
Huang X, Li C, Li WH, Luo YL, Wang B, Zhang W, Gan JJ, Ji JL. Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial. Hum Psychopharmacol. 2013;28(6):594–9. https://doi.org/10.1002/hup.2361.
Article CAS PubMed Google Scholar
Huang X, Kang Y, Jiang X, Yang J, Wu AG, Zhang C, Qin D, Cao S, Mei Q, Ye Y, Wu J. Tandospirone enhances the anti-myocardial fibrosis effect of valsartan in spontaneously hypertensive rats. Biomed Pharmacother. 2020;126:110073. https://doi.org/10.1016/j.biopha.2020.110073. Epub 2020 Mar 13
Article CAS PubMed Google Scholar
Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001;76(5):1521–31. https://doi.org/10.1046/j.1471-4159.2001.00154.x.
Article CAS PubMed Google Scholar
Iizawa A, Oshima T, Kasuya Y, Dohi S. Oral tandospirone and clonidine provide similar relief of preoperative anxiety. Can J Anaesth. 2004;51(7):668–71. https://doi.org/10.1007/BF03018423.
Article PubMed Google Scholar
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, Tariot P, Yaffe K. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33(5):957–70. https://doi.org/10.1038/sj.npp.1301492. Epub 2007 Jul 18
Article CAS PubMed Google Scholar
Jin YH, Akaike N. Tandospirone-induced K+ current in acutely dissociated rat dorsal raphe neurones. Br J Pharmacol. 1998;124(5):897–904. https://doi.org/10.1038/sj.bjp.0701922.
Article CAS PubMed PubMed Central Google Scholar
Jin M, Mo Y, Ye K, Chen M, Liu Y, He C. Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis. Arch Med Sci. 2019;15(1):23–32. https://doi.org/10.5114/aoms.2017.69234. Epub 2017 Jul 31
Article CAS PubMed Google Scholar
Joëls M, Shinnick-Gallagher P, Gallagher JP. Effect of serotonin and serotonin analogues on passive membrane properties of lateral septal neurons in vitro. Brain Res. 1987;417(1):99–107. https://doi.org/10.1016/0006-8993(87)90183-1.
Article PubMed Google Scholar
Kagota S, Morikawa K, Ishida H, Chimoto J, Maruyama-Fumoto K, Yamada S, Shinozuka K. Vasorelaxant effects of benzodiazepines, non-benzodiazepine sedative-hypnotics, and tandospirone on isolated rat arteries. Eur J Pharmacol. 2021;892:173744. https://doi.org/10.1016/j.ejphar.2020.173744. Epub 2020 Nov 19
Article CAS PubMed Google Scholar
Kalkstein S, Hurford I, Gur RC. Neurocognition in schizophrenia. Curr Top Behav Neurosci. 2010;4:373–90. https://doi.org/10.1007/7854_2010_42.
Article PubMed Google Scholar
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–96. https://doi.org/10.1001/archpsyc.1988.01800330013001.
Article CAS PubMed Google Scholar
Kaneda Y, Morimoto T, Fujii A. Gynecomastia induced by treatment with tandospirone, a 5-HT1A agonist. J Psychiatry Neurosci. 2001;26(2):152–3.
CAS PubMed PubMed Central Google Scholar
Katayama J, Yakushiji T, Akaike N. Characterization of the K+ current mediated by 5-HT1A receptor in the acutely dissociated rat dorsal raphe neurons. Brain Res. 1997;745(1–2):283–92. https://doi.org/10.1016/s0006-8993(96)01141-9.
Article CAS PubMed Google Scholar
Kawano T, Kosuge T, Takagi S, Shimoyama A, Harunari N, Tahara Y, Suzuki N. First death case of serotonin syndrome in Japan induced by fluvoxamine and tandospirone. Chudoku Kenkyu. 2011;24(4):305–10. Japanese
PubMed Google Scholar
Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut. 2006;55(12):1685–91. https://doi.org/10.1136/gut.2005.085365. Epub 2006 Jul 19
Article CAS PubMed PubMed Central Google Scholar
Kinoshita Y, Hashimoto T, Kawamura A, Yuki M, Amano K, Sato H, Adachi K, Sato S, Oshima N, Takashima T, Kitajima N, Abe K, Suetsugu H. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther. 2005;21(Suppl 2):37–41. https://doi.org/10.1111/j.1365-2036.2005.02472.x.
Article CAS PubMed Google Scholar
Kishi T, Meltzer HY, Matsuda Y, Iwata N. Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis. Psychol Med. 2014;44(11):2255–69. https://doi.org/10.1017/S0033291713002857. Epub 2013 Nov 21
Article CAS PubMed Google Scholar
Kremen WS, Seidman LJ, Pepple JR, Lyons MJ, Tsuang MT, Faraone SV. Neuropsychological risk indicators for schizophrenia: a review of family studies. Schizophr Bull. 1994;20(1):103–19. https://doi.org/10.1093/schbul/20.1.103.
Article CAS PubMed Google Scholar
Lacivita E, Di Pilato P, De Giorgio P, Colabufo NA, Berardi F, Perrone R, Leopoldo M. The therapeutic potential of 5-HT1A receptors: a patent review. Expert Opin Ther Pat. 2012;22(8):887–902. https://doi.org/10.1517/13543776.2012.703654. Epub 2012 Jul 13
Article CAS PubMed Google Scholar
Lakhlani PP, MacMillan LB, Guo TZ, McCool BA, Lovinger DM, Maze M, Limbird LE. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA. 1997;94(18):9950–5. https://doi.org/10.1073/pnas.94.18.9950.
Article CAS PubMed PubMed Central Google Scholar
Lin J, Su Y, Wang C, Yang F, Xu Y, Yuan Y, Yuan Y, Wang X, Yu X, Si T. Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: a multicenter, randomized, parallel-controlled, open-label study. J Psychiatr Res. 2018;99:104–10. https://doi.org/10.1016/j.jpsychires.2018.01.020. Epub 2018 Feb 10
Article PubMed Google Scholar
Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52(10):982–8. https://doi.org/10.1001/archneur.1995.00540340074015.
Article CAS PubMed Google Scholar
Lucki I, Rickels K, Giesecke MA, Geller A. Differential effects of the anxiolytic drugs, diazepam and buspirone, on memory function. Br J Clin Pharmacol. 1987;23(2):207–11. https://doi.org/10.1111/j.1365-2125.1987.tb03031.x.
Article CAS PubMed PubMed Central Google Scholar
Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104–10. https://doi.org/10.1523/JNEUROSCI.20-24-09104.2000.
Article CAS PubMed PubMed Central Google Scholar
Mandrioli R, Mercolini L, Raggi MA. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab. 2010;11(9):815–29. https://doi.org/10.2174/138920010794328887.
Article CAS PubMed Google Scholar
Martin KF, Mason R. Isapirone is a partial agonist at 5-hydroxytryptamine 1A (5-HT1A) receptors in the rat hippocampus: electrophysiological evidence. Eur J Pharmacol. 1987;141(3):479–83. https://doi.org/10.1016/0014-2999(87)90569-3.
Article CAS PubMed Google Scholar
Masuda Y, Akagawa Y, Hishikawa Y. Effect of serotonin 1A agonist tandospirone on depression symptoms in senile patients with dementia. Hum Psychopharmacol. 2002;17(4):191–3. https://doi.org/10.1002/hup.393.
Article CAS PubMed Google Scholar
Matheson GK, Pfeifer DM, Weiberg MB, Michel C. The effects of azapirones on serotonin1A neurons of the dorsal raphe. Gen Pharmacol. 1994;25(4):675–83. https://doi.org/10.1016/0306-3623(94)90245-3.
Article CAS PubMed Google Scholar
Maura G, Raiteri M. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem. 1996;66(1):203–9. https://doi.org/10.1046/j.1471-4159.1996.66010203.x.
Article CAS PubMed Google Scholar
Maura G, Roccatagliata E, Raiteri M. Serotonin autoreceptor in rat hippocampus: pharmacological characterization as a subtype of the 5-HT1 receptor. Naunyn Schmiedeberg’s Arch Pharmacol. 1986;334(4):323–6. https://doi.org/10.1007/BF00569364.
Article CAS Google Scholar
McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D₂ receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology. 2007;32(1):78–94. https://doi.org/10.1038/sj.npp.1301098. Epub 2006 May 17
Article CAS PubMed Google Scholar
McLean SL, Idris NF, Woolley ML, Neill JC. D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol. 2009a;19(6):440–50. https://doi.org/10.1016/j.euroneuro.2009.01.009. Epub 2009 Mar 5
Article CAS PubMed Google Scholar
McLean SL, Woolley ML, Thomas D, Neill JC. Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology. 2009b;206(3):403–14. https://doi.org/10.1007/s00213-009-1618-0. Epub 2009 Jul 21
Article CAS PubMed Google Scholar
Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177–97. https://doi.org/10.1016/S0079-6123(08)00909-6.
Article CAS PubMed Google Scholar
Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, Shemer A. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol. 1992;12(5):341–5.
Article CAS PubMed Google Scholar
Miwa H, Nagahara A, Tominaga K, Yokoyama T, Sawada Y, Inoue K, Ashida K, Fukuchi T, Hojo M, Yamashita H, Tomita T, Hori K, Oshima T. Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial. Am J Gastroenterol. 2009;104(11):2779–87. https://doi.org/10.1038/ajg.2009.427. Epub 2009 Jul 28
Article CAS PubMed Google Scholar
Monte TL, Rieder CR, Tort AB, Rockenback I, Pereira ML, Silveira I, Ferro A, Sequeiros J, Jardim LB. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand. 2003;107(3):207–10. https://doi.org/10.1034/j.1600-0404.2003.02132.x.
Article CAS PubMed Google Scholar
Moskowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry. 1982;43(12 Pt 2):45–55.
CAS PubMed Google Scholar
Moss LE, Neppe VM, Drevets WC. Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1993;13(3):204–9.
Article CAS PubMed Google Scholar
Murata Y, Yanagihara Y, Mori M, Mine K, Enjoji M. Chronic treatment with tandospirone, a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in hippocampal neurogenesis and behavior. J Affect Disord. 2015;180:1–9. https://doi.org/10.1016/j.jad.2015.03.054. Epub 2015 Apr 3
Article CAS PubMed Google Scholar
Murphy JM, Horton NJ, Laird NM, Monson RR, Sobol AM, Leighton AH. Anxiety and depression: a 40-year perspective on relationships regarding prevalence, distribution, and comorbidity. Acta Psychiatr Scand. 2004;109(5):355–75. https://doi.org/10.1111/j.1600-0447.2003.00286.x.
Article CAS PubMed Google Scholar
Natsui K, Mizuno Y, Tani N, Yabuki M, Komuro S. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2007;32(4):233–40. https://doi.org/10.1007/BF03191009.
Article CAS PubMed Google Scholar
Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol. 1995;5(3):239–44. https://doi.org/10.1016/1047-2797(94)00112-7.
Article CAS PubMed Google Scholar
Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verrièle L, Audinot V, Millan MJ. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998;355(2–3):245–56. https://doi.org/10.1016/s0014-2999(98)00483-x.
Article CAS PubMed Google Scholar
Newton RE, Casten GP, Alms DR, Benes CO, Marunycz JD. The side effect profile of buspirone in comparison to active controls and placebo. J Clin Psychiatry. 1982;43(12 Pt 2):100–2.
CAS PubMed Google Scholar
Niendam TA, Bearden CE, Johnson JK, McKinley M, Loewy R, O’Brien M, Nuechterlein KH, Green MF, Cannon TD. Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res. 2006;84(1):100–11. https://doi.org/10.1016/j.schres.2006.02.005. Epub 2006 Mar 24
Article PubMed Google Scholar
Nishikawa H, Inoue T, Masui T, Izumi T, Koyama T. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007a;31(4):926–31. https://doi.org/10.1016/j.pnpbp.2007.02.010. Epub 2007 Feb 23
Article CAS Google Scholar
Nishikawa H, Inoue T, Izumi T, Koyama T. Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats. Eur Neuropsychopharmacol. 2007b;17(10):643–50. https://doi.org/10.1016/j.euroneuro.2007.02.010. Epub 2007 Mar 21
Article CAS PubMed Google Scholar
Nishitsuji K, To H, Murakami Y, Kodama K, Kobayashi D, Yamada T, Kubo C, Mine K. Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. Clin Drug Investig. 2004;24(2):121–6. https://doi.org/10.2165/00044011-200424020-00007.
Article CAS PubMed Google Scholar
Nishitsuji K, To H, Shimizu T, Yanase Y, Yamada T, Hara C, Mine K, Higuchi S. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur Neuropsychopharmacol. 2006;16(5):376–82. https://doi.org/10.1016/j.euroneuro.2005.11.009. Epub 2006 Jan 6
Article CAS PubMed Google Scholar
Noyes R Jr. Comorbidity in generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):41–55. https://doi.org/10.1016/s0193-953x(05)70205-7.
Article PubMed Google Scholar
Okita K, Shiina A, Nakazato M, Iyo M. Tandospirone, a 5-HT1A partial agonist is effective in treating anorexia nervosa: a case series. Ann General Psychiatry. 2013;12(1):7. https://doi.org/10.1186/1744-859X-12-7.
Article Google Scholar
Olsen AS, Sozda CN, Cheng JP, Hoffman AN, Kline AE. Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone. J Neurotrauma. 2012;29(10):1898–907. https://doi.org/10.1089/neu.2012.2358. Epub 2012 Apr 23
Article PubMed PubMed Central Google Scholar
Oshima T, Kasuya Y, Terazawa E, Nagase K, Saitoh Y, Dohi S. The anxiolytic effects of the 5-hydroxytryptamine-1A agonist tandospirone before otolaryngologic surgery. Anesth Analg. 2001;93(5):1214–6. https://doi.org/10.1097/00000539-200111000-00034.
Article CAS PubMed Google Scholar
Oshima T, Kasuya Y, Okumura Y, Terazawa E, Dohi S. Prevention of nausea and vomiting with tandospirone in adults after tympanoplasty. Anesth Analg. 2002;95(5):1442–5. https://doi.org/10.1097/00000539-200211000-00063. Table of contents
Article CAS PubMed Google Scholar
Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW. Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health. 1990;80(12):1467–70. https://doi.org/10.2105/ajph.80.12.1467.
Article CAS PubMed PubMed Central Google Scholar
Oyamada Y, Horiguchi M, Rajagopal L, Miyauchi M, Meltzer HY. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behav Brain Res. 2015;285:165–75. https://doi.org/10.1016/j.bbr.2014.09.040. Epub 2014 Oct 16
Article CAS PubMed Google Scholar
Pascalis O, Hunkin NM, Bachevalier J, Mayes AR. Change in background context disrupts performance on visual paired comparison following hippocampal damage. Neuropsychologia. 2009;47(10):2107–13. https://doi.org/10.1016/j.neuropsychologia.2009.04.001. Epub 2009 Apr 9
Article CAS PubMed Google Scholar
Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. Brain Res. 1985;346(2):205–30. https://doi.org/10.1016/0006-8993(85)90856-x.
Article CAS PubMed Google Scholar
Penington NJ, Kelly JS, Fox AP. Whole-cell recordings of inwardly rectifying K+ currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat. J Physiol. 1993;469:387–405. https://doi.org/10.1113/jphysiol.1993.sp019819.
Article CAS PubMed PubMed Central Google Scholar
Petrik D, Lagace DC, Eisch AJ. The neurogenesis hypothesis of affective and anxiety disorders: are we mistaking the scaffolding for the building? Neuropharmacology. 2012;62(1):21–34. https://doi.org/10.1016/j.neuropharm.2011.09.003. Epub 2011 Sep 19
Article CAS PubMed Google Scholar
Piñeyro G, Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev. 1999;51(3):533–91.
PubMed Google Scholar
Pliszka SR, Rogeness GA, Medrano MA. DBH, MHPG, and MAO in children with depressive, anxiety, and conduct disorders: relationship to diagnosis and symptom ratings. Psychiatry Res. 1988;24(1):35–44. https://doi.org/10.1016/0165-1781(88)90137-0.
Article CAS PubMed Google Scholar
Pollard GT, Nanry KP, Howard JL. Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol. 1992;221(2–3):297–305. https://doi.org/10.1016/0014-2999(92)90716-h.
Article CAS PubMed Google Scholar
Quartermain D, Clemente J, Shemer A. 5-HT1A agonists disrupt memory of fear conditioning in mice. Biol Psychiatry. 1993;33(4):247–54. https://doi.org/10.1016/0006-3223(93)90290-t.
Article CAS PubMed Google Scholar
Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol. 1992;136(7):873–83. https://doi.org/10.1093/aje/136.7.873.
Article CAS PubMed Google Scholar
Redmond DE Jr, Katz MM, Maas JW, Swann A, Casper R, Davis JM. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects. Arch Gen Psychiatry. 1986;43(10):938–47. https://doi.org/10.1001/archpsyc.1986.01800100028005.
Article PubMed Google Scholar
Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982;43(12 Pt 2):81–6.
CAS PubMed Google Scholar
Roy A, Jimerson DC, Pickar D. Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test. Am J Psychiatry. 1986;143(7):846–51. https://doi.org/10.1176/ajp.143.7.846.
Article CAS PubMed Google Scholar
Samuels BA, Hen R. Neurogenesis and affective disorders. Eur J Neurosci. 2011;33(6):1152–9. https://doi.org/10.1111/j.1460-9568.2011.07614.x.
Article PubMed Google Scholar
Sareen J, Cox BJ, Afifi TO, de Graaf R, Asmundson GJ, ten Have M, Stein MB. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry. 2005;62(11):1249–57. https://doi.org/10.1001/archpsyc.62.11.1249.
Article PubMed Google Scholar
Sasa M. A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone). Nihon Shinkei Seishin Yakurigaku Zasshi. 1997;17(2):53–9. Japanese
CAS PubMed Google Scholar
Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int J Neuropsychopharmacol. 2007;10(2):281–3. https://doi.org/10.1017/S1461145706007000. Epub 2006 Jul 3
Article CAS PubMed Google Scholar
Saykin AJ, Gur RC, Gur RE, Mozley PD, Mozley LH, Resnick SM, Kester DB, Stafiniak P. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry. 1991;48(7):618–24. https://doi.org/10.1001/archpsyc.1991.01810310036007.
Article CAS PubMed Google Scholar
Schaffler K, Klausnitzer W. Placebo-controlled study on acute and subchronic effects of buspirone vs bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers. Pharmacopsychiatry. 1989;22(1):26–33. https://doi.org/10.1055/s-2007-1014573.
Article CAS PubMed Google Scholar
Schramm NL, McDonald MP, Limbird LE. The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci. 2001;21(13):4875–82. https://doi.org/10.1523/JNEUROSCI.21-13-04875.2001.
Article CAS PubMed PubMed Central Google Scholar
Sevy S, Papadimitriou GN, Surmont DW, Goldman S, Mendlewicz J. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry. 1989;25(2):141–52. https://doi.org/10.1016/0006-3223(89)90158-3.
Article CAS PubMed Google Scholar
Seymour PA, Mena EE, McLean S, Heym J. Pharmacology of the serotonergic anxiolytic tandospirone (SM-3997). Prog Clin Biol Res. 1990;361:453–60.
CAS PubMed Google Scholar
Shimizu H, Hirose A, Tatsuno T, Nakamura M, Katsube J. Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate. Jpn J Pharmacol. 1987;45(4):493–500. https://doi.org/10.1254/jjp.45.493.
Article CAS PubMed Google Scholar
Shimizu H, Tatsuno T, Hirose A, Tanaka H, Kumasaka Y, Nakamura M. Characterization of the putative anxiolytic SM-3997 recognition sites in rat brain. Life Sci. 1988a;42(24):2419–27. https://doi.org/10.1016/0024-3205(88)90340-2.
Article CAS PubMed Google Scholar
Shimizu H, Karai N, Hirose A, Tatsuno T, Tanaka H, Kumasaka Y, Nakamura M. Interaction of SM-3997 with serotonin receptors in rat brain. Jpn J Pharmacol. 1988b;46(3):311–4. https://doi.org/10.1254/jjp.46.311.
Article CAS PubMed Google Scholar
Smiley A, Moskowitz H. Effects of long-term administration of buspirone and diazepam on driver steering control. Am J Med. 1986;80(3B):22–9. https://doi.org/10.1016/0002-9343(86)90328-1.
Article CAS PubMed Google Scholar
Snigdha S, Neill JC. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res. 2008;191(1):26–31. https://doi.org/10.1016/j.bbr.2008.03.018. Epub 2008 Mar 22
Article CAS PubMed Google Scholar
Sprouse JS, Aghajanian GK. (−)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists. Eur J Pharmacol. 1986;128(3):295–8. https://doi.org/10.1016/0014-2999(86)90782-x.
Article CAS PubMed Google Scholar
Stefănescu AM, Popa M, Dumitriu L. Direct assay of 3-methoxy-4-hydroxy-phenylglycol (MHPG) in human saliva; a new approach in the assessment of noradrenergic function. Endocrinologie. 1989;27(2):93–6.
PubMed Google Scholar
Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv. 2006;57(5):673–80. https://doi.org/10.1176/ps.2006.57.5.673.
Article PubMed Google Scholar
Sumitomo Pharmaceutical (Suzhou) Co., Ltd. Pharmaceutical instructions of tandospirone. EB/OL. 2020. http://www.dsmpharm.com.cn/dsm_admin/attachment/download/Sediel0824.pdf
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol. 2000;20(3):386–8. https://doi.org/10.1097/00004714-200006000-00019.
Article CAS PubMed Google Scholar
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry. 2001a;49(10):861–8. https://doi.org/10.1016/s0006-3223(00)01025-8.
Article CAS PubMed Google Scholar
Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry. 2001b;158(10):1722–5. https://doi.org/10.1176/appi.ajp.158.10.1722.
Article CAS PubMed Google Scholar
Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2007a;95(1–3):158–68. https://doi.org/10.1016/j.schres.2007.06.008. Epub 2007 Jul 12
Article PubMed Google Scholar
Sumiyoshi T, Higuchi Y, Matsui M, Arai H, Takamiya C, Meltzer HY, Kurachi M. Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2007b;31(4):965–7. https://doi.org/10.1016/j.pnpbp.2007.02.017. Epub 2007 Mar 3
Article CAS Google Scholar
Suzuki M, Uchiumi M, Murasaki M. Effects of tandospirone, a 5-HT1A receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam. Yakubutsu Seishin Kodo. 1993;13(4):213–24.
CAS PubMed Google Scholar
Takahashi M, Iwamoto K, Kawamura Y, Nakamura Y, Ishihara R, Uchiyama Y, Ebe K, Noda A, Noda Y, Yoshida K, Iidaka T, Ozaki N. The effects of acute treatment with tandospirone, diazepam, and placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol. 2010;25(3):260–7. https://doi.org/10.1002/hup.1105.
Article CAS PubMed Google Scholar
Takei A, Honma S, Kawashima A, Yabe I, Fukazawa T, Hamada K, Hamada T, Tashiro K. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2002;56(2):181–5. https://doi.org/10.1046/j.1440-1819.2002.00952.x.
Article PubMed Google Scholar
Takei A, Hamada T, Yabe I, Sasaki H. Treatment of cerebellar ataxia with 5-HT1A agonist. Cerebellum. 2005;4(3):211–5. https://doi.org/10.1080/14734220500222318.
Article CAS PubMed Google Scholar
Tamai H, Komaki G, Kubota S, Kobayashi N, Matsubayashi S, Mori K, Nakagawa T, Takayama T, Kimura M, Kumagai LF. The clinical efficacy of a 5-HT1A agonist, SM-3997, in the treatment of bulimia. Int J Obes. 1990;14(3):289–92.
CAS PubMed Google Scholar
Tanaka H, Shimizu H, Tatsuno T, Hirose A, Kumasaka Y, Nakamura M. Autoradiographic evidence for the interaction of SM-3997 with 5-HT1A receptors in the rat brain. Jpn J Pharmacol. 1990;52(3):504–7. https://doi.org/10.1254/jjp.52.504.
Article CAS PubMed Google Scholar
Tanaka H, Shimizu H, Kumasaka Y, Hirose A, Tatsuno T, Nakamura M. Autoradiographic localization and pharmacological characterization of [3H]tandospirone binding sites in the rat brain. Brain Res. 1991;546(2):181–9. https://doi.org/10.1016/0006-8993(91)91479-k.
Article CAS PubMed Google Scholar
Tanaka H, Tatsuno T, Shimizu H, Hirose A, Kumasaka Y, Nakamura M. Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen Pharmacol. 1995;26(8):1765–72. https://doi.org/10.1016/0306-3623(95)00077-1.
Article CAS PubMed Google Scholar
Targum SD, Wedel PC, Fava M. Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder. J Psychiatr Res. 2015;68:392–6. https://doi.org/10.1016/j.jpsychires.2015.04.024. Epub 2015 May 9
Article PubMed Google Scholar
Tollefson GD, Lancaster SP, Montague-Clouse J. The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency. Psychopharmacol Bull. 1991;27(2):163–70.
CAS PubMed Google Scholar
van Laar MW, Volkerts ER, van Willigenburg AP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol. 1992;12(2):86–95.
PubMed Google Scholar
Vergé D, Daval G, Marcinkiewicz M, Patey A, el Mestikawy S, Gozlan H, Hamon M. Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci. 1986;6(12):3474–82. https://doi.org/10.1523/JNEUROSCI.06-12-03474.1986.
Article PubMed PubMed Central Google Scholar
Waddington JL, Lane A, Scully PJ, Larkin C, O’Callaghan E. Neurodevelopmental and neuroprogressive processes in schizophrenia. Antithetical or complementary, over a lifetime trajectory of disease? Psychiatr Clin North Am. 1998;21(1):123–49. https://doi.org/10.1016/s0193-953x(05)70364-6.
Article CAS PubMed Google Scholar
Wickman K, Clapham DE. Ion channel regulation by G proteins. Physiol Rev. 1995;75(4):865–85. https://doi.org/10.1152/physrev.1995.75.4.865.
Article CAS PubMed Google Scholar
Winslow JW, Bradley JD, Smith JA, Neer EJ. Reactive sulfhydryl groups of alpha 39, a guanine nucleotide-binding protein from brain. Location and function. J Biol Chem. 1987;262(10):4501–7.
Article CAS PubMed Google Scholar
Yamada K, Yagi G, Kanba S. Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: a randomized controlled trial. Psychiatry Clin Neurosci. 2003;57(2):183–7. https://doi.org/10.1046/j.1440-1819.2003.01099.x.
Article CAS PubMed Google Scholar
Yamauchi K, Yamada S, Morita K, Maeda H, Tanaka M. Comparative study of short-term anxiolytic potency of alprazolam and tandospirone in psychiatric outpatients with anxiety disorders. Hum Psychopharmacol. 2001;16(6):469–73. https://doi.org/10.1002/hup.316.
Article CAS PubMed Google Scholar
Yang RK, Yehuda R, Holland DD, Knott PJ. Relationship between 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in saliva and plasma of healthy volunteers. Biol Psychiatry. 1997;42(9):821–6. https://doi.org/10.1016/s0006-3223(97)00055-3.
Article CAS PubMed Google Scholar
Yocca FD, Hyslop DK, Smith DW, Maayani S. BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT1A receptor in rat and guinea pig hippocampal membranes. Eur J Pharmacol. 1987;137(2–3):293–4. https://doi.org/10.1016/0014-2999(87)90241-x.
Article CAS PubMed Google Scholar
Zhang HW. Research progress on clinical application of tandospirone. Chin Med. 2010;5(2):186–7.
Google Scholar

Download references

Author information

Authors and Affiliations

Tianjin Mental Health Institute, Tianjin Anding Hospital, Tianjin, China
Jie Li

Authors

Jie Li
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jie Li .

Editor information

Editors and Affiliations

Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany
Peter Riederer
Inst für Psychologische Medizin, Haag, Bayern, Germany
Gerd Laux
Fujita Health University School Medicine, Toyoake, Aichi, Japan
Toshiharu Nagatsu
Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China
Weidong Le
Würzburg, Bayern, Germany
Christian Riederer

Section Editor information

Centre for Addiction and Mental Health; Department of Psychiatry, University of Toronto, Toronto, ON, Canada
Stefan Kloiber

Rights and permissions

Reprints and permissions

Copyright information

About this entry

Cite this entry

Li, J. (2021). Tranquilizer/Anxiolytics: Tandospirone. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_167-1

Download citation

DOI: https://doi.org/10.1007/978-3-319-56015-1_167-1
Received: 19 April 2021
Accepted: 20 April 2021
Published: 16 July 2021
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics